Treatment of iron deficiency with or without anaemia with intravenous ferric carboxymaltose in gynaecological practices - A non-interventional study

Geburtshilfe und Frauenheilkunde

Volumn 74, Issue 1, 2014, Pages 81-88

  Herfs, R ^a   Fleitmann, L ^b   Kocsis, I ^a  

^a Gynaecology and Obstetrics Practice   (Germany)

^b Dortmund Gynaecology and Obstetrics   (Germany)

Author keywords

ferric carboxymaltose; hypermenorrhoea; intravenous iron substitution; iron deficiency anaemia; menorrhagia; post partum

Indexed keywords

FERRIC CARBOXYMALTOSE; FERRITIN; HEMOGLOBIN; IRON; TRANSFERRIN;

ADULT; ALOPECIA; ARTICLE; BOLUS INJECTION; CONCENTRATION LOSS; DEPRESSED BLOOD PRESSURE; DEPRESSION; DRUG EFFICACY; DRUG ERUPTION; DRUG HYPERSENSITIVITY; DRUG INDICATION; DRUG TOLERABILITY; DYSPNEA; FATIGUE; FEMALE; FERRITIN BLOOD LEVEL; GYNECOLOGY; HEADACHE; HUMAN; IRON DEFICIENCY; IRON DEFICIENCY ANEMIA; IRON INTAKE; IRON RESTRICTION; IRON STORAGE; IRON THERAPY; MAJOR CLINICAL STUDY; MENORRHAGIA; NAUSEA; PALLOR; PROSPECTIVE STUDY; PRURITUS; PUERPERIUM; SLEEP DISORDER; TREATMENT DURATION; VEGETARIAN;

EID: 84893503471     PISSN: 00165751     EISSN: 14388804     Source Type: Journal    
DOI: 10.1055/s-0033-1360223     Document Type: Article

References (48)

1. WHO CDC Assessing the iron status of populations 2004. Online: http://who.int/publications/2004/9241593156-eng.pdf last access: 29.03.2012
2. Hastka J., Heimpel H., Metzgeroth G. Leitlinien der Deutschen Gesellschaft für Hämatologie und Onkologie (DGHO) zu Eisenmangel und Eisenmangelanämie 2011. Online: http://dgho-onkopedia.de/onkopedia/ leitlinien/eisenmangel-und-eisenmangelanemie last access: 14.01.2014
3. McLean E., Cogswell M., Egli I. et al. Worldwide prevalence of anemia. WHO Vitamin and Mineral Nutrition Information System 1993-2005. Public Health Nutr: 2009; 12 444 454
4. Lyseng-Williamson K. A., Keating G. M. Ferric carboxymaltose. A review of its use in iron-deficiency anemia. Drugs: 2009; 69 739 756
5. Moore A. R., Gaskell H., Rose P. et al. Meta-analysis of efficacy and safety of intravenous ferric carboxymaltose (Ferinject) from clinical trial reports and published data. BMC Blood Disorders: 2011; 11 4
6. Locatelli F., Pisoni R. L., Combe C. Anemia in haemodialysis patients of five European countries: association with morbidity and mortality in the Dialysis Outcome and Practice Patterns Study (DOPPS). Nephrol Dialysis Transplant: 2004; 19 121 132 (Pubitemid 38072623)
7. Dietzfelbinger H., Hubmann M. Eisenmangelanämie. DBI: 2012; 2 6 16
8. Deutsche Gesellschaft für Ernährung (DGE) Referenzwerte für die Nährstoffzufuhr. Online: http://www.dge.de/modules.php?name= Content&pa=showpage&pid=3&page=8 last access: 14.01.2014
9. Nationale Verzehrstudie II von 01/2008 des Bundesministeriums für Ernährung, Landwirtschaft und Verbraucherschutz. Ernährung: 2008; 2 77 81
10. Marret H., Fauconnier A., Chabbert-Buffet N. et al. Clinical practice guidelines on menorrhagia: Management of abnormal uterine bleeding before menopause. Eur J Obstet Gynecol Reprod Biol: 2010; 152 133 137
11. Quinbi W. Y. The efficacy and safety of current intravenous iron preparations for the management of iron-deficiency anemia: a review. Arzneimittelforsch: 2010; 60 6a 399 412
12. Liu Z., Doan Q. V., Blumenthal P. et al. A systematic review evaluating health-related quality of life, work impairment, and health-care costs and utilization in abnormal uterine bleeding. Value Health: 2007; 10 183 194 (Pubitemid 46802276)
13. Pfenniger A., Schuller C., Christoph P. et al. Safety and efficacy of high-dose iron carboxymaltose vs. iron sucrose for treatment of postpartum anaemia. J Perinat Med: 2012; 40 397 402
14. Muñoz M., Garcia-Erce A., Remacha A. F. Disorders of iron metabolism. Part II: iron deficiency and iron overload. J Clin Pathol: 2011; 64 287 296
15. Cook J. D. Diagnosis and management of iron-deficiency anemia. Best Pract Res Clin Haematol: 2005; 18 319 323
16. Weiss G., Goodnough L. T. Anemia of chronic disease. N Engl J Med: 2005; 352 1011 1023
17. Moreno F., Sanz-Guajardo D., Lopez-Gomez J. M. et al. Increasing the hematocrit has a beneficial effect on quality of life and is safe in selected hemodialysis patients: Spanish Cooperative Renal Patients Quality of Life Study Group of the Spanish Society of Nephrology. J Am Soc Nephrol: 2000; 11 335 342 (Pubitemid 30064857)
18. Littlewood T. J., Bajetta E., Nortier J. W. et al. Effects of epoetin alfa on hematologic parameters and quality of life in cancer patients receiving non-platinum chemotherapy: results of a randomized, double blind, placebo-controlled trial. J Clin Oncol: 2001; 19 2865 2874 (Pubitemid 32538196)
19. Van Wyck D. B., Mangione A., Morrison J. et al. Large-dose intravenous ferric carboxymaltose injections for iron deficiency anemia in heavy uterine bleeding: a randomized, controlled trial. Transfusion: 2009; 49 2719 2728
20. Dietzfelbinger H. Richtlinien zur Behandlung des Eisenmangels. Tempo Medical: 1997; 19 16 24
21. Dietzfelbinger H., Kaboth W., Theml H. Eisenmangelanämie. Intern Prax: 1980; 20 395 408
22. Hershko C., Skikne B. Pathogenesis and management of iron deficiency anemia: emerging role of celiac disease, Helicobacter pylori, and autoimmune gastritis. Seminars in Hematology: 2009; 46 339 350
23. Lipp H. P. Peroral und intravenös anwendbare Eisenpräparate. Krankenhauspharmazie: 2011; 32 450 459
24. Schaefer R. M. Eisenmangel - mit und ohne Anämie - behandelt. Allgemeinarzt: 2011; 18 42 46
25. Bergmann R. L., Dudenhausen J. W., Ennen J. C. et al. Diagnostik und Behandlung der Anämie und des Eisenmangels in der Schwangerschaft und im Wochenbett. Literaturüberblick und Empfehlungen. Geburtsh Frauenheilk: 2009; 69 682 686
26. Link H. Anämie bei Krebs. Der Onkologe: 2009; 2 1 8
27. Beglinger C., Breymann C. Behandlung von Eisenmangel. Wie sind die praktischen Erfahrungen mit oralen und i.v. Eisenpräparaten? Schweiz Med Forum: 2010; 10 1 6
28. Geisser P. Pharmakologie und Sicherheitsprofil von Ferric Carboxymaltose (Ferinject®): Struktur/Reaktivitäts-Verhältnisse von Eisenpräparaten. Port J Nephrol Hypert: 2009; 23 11 16
29. Breymann C., Römer T., Dudenhausen J. W. Treatment of iron deficiency in women. Geburtsh Frauenheilk: 2013; 73 256 261
30. Vifor Pharma Fachinformation - ferinject®, Oktober 2013.
31. Quinbi W., Martinez C., Smith M. et al. A randomized controlled trial comparing intravenous ferric carboxymaltose with oral iron for treatment of iron deficiency anaemia of non-dialysis-dependent chronic kidney disease patients. Nephrol Dial Transplant: 2011; 26 1599 1607
32. Kulnigg S., Stoinov S., Simanenkov V. et al. A novel intravenous iron formulation for treatment of anemia in inflammatory bowel disease: the ferric carboxymaltose (Ferinject®) randomized controlled trial. Am J Gastroenterol: 2008; 103 1182 1192 (Pubitemid 351677967)
33. Anker S. D., Comin C. J., Filippatos G. et al. Ferric carboxymaltose in patients with heart failure and iron deficiency. N Engl J Med: 2009; 361 2436 2448
34. Anker S. D., Comin-Colet J., Filipatos G. et al. Rationale and design of Ferinject® Assessment in patients with IRon deficiency and chronic Heart Failure (FAIR-HF) study: a randomized, placebo-controlled study of intravenous iron supplementation in patients with and without anaemia. Eur J Heart Fail: 2009; 11 1084 1091
35. Seid M. H., Derman R. J., Baker B. J. et al. Ferric carboxymaltose injection in the treatment of postpartum iron deficiency anemia: a randomized controlled clinical trial. Am J Obstet Gynecol: 2008; 199 435.e1 435.e7
36. Van Wyck D. B., Martens M. G., Seid M. H. et al. Intravenous ferric carboxymaltose compared with oral iron in the treatment of postpartum anemia. A randomized controlled trial. Obstet Gynaecol: 2007; 110 267 278 (Pubitemid 47356650)
37. Muñoz M., Martin-Montanez E. Ferric carboxymaltose for the treatment of iron deficiency anemia. Expert Opin Pharmacother: 2012; 13 907 921
38. Breymann C., Glia F., Bejenariu C. et al. Comparative efficacy and safety of intravenous ferric carboxymaltose in the treatment of postpartum iron deficiency anemia. Int J Gynecol Obstet: 2008; 101 67 73
39. Gesetz über den Verkehr mit Arzneimitteln (Arzneimittelgesetz - AMG) in der Fassung vom 19.10.2012; http://www.gesetze-im-internet.de/bundesrecht/ amg-1976/gesamt.pdf
40. Verband forschender Pharma-Unternehmen Register nicht-interventioneller Studien. Online: http://www.vfa.de/de/arzneimittel-forschung/datenbanken-zu- arzneimitteln/nisdb/nis-details/-551 last access: 14.01.2014
41. European Medicines Agency EMEA Guideline on pharmacovigilance practices. 2012. Online: http://www.ema.europa.eu/docs/en-GB/document-libery/scientific- guideline/2012/06/WC500129136.pdf last access: 14.01.2014
42. Raspe F., Breymann C. Diagnosis and therapy of anaemia in pregnancy and puerperium - a survey of obstetric clinics in Switzerland. Geburtsh Frauenheilk: 2011; 71 595 600
43. Fletes R., Lazarus J. M., Gage J. et al. Suspected iron dextran-related adverse drug events in hemodialysis patients. Am J Kidney Dis: 2001; 37 743 749 (Pubitemid 32268035)
44. Sanofi Aventis Ferrlecit summary of product characteristics. September 2013.
45. Vifor Pharma Ltd. Venofer summary of product characteristics. September 2013.
46. Crichton R. R., Danielson B. G., Geisser P. Iron Therapy - with special Emphasis on intravenous Administration. 4th ed. Bremen UNI-Med: 2008; 71
47. Bailie G. R. Breaking new ground in intravenous iron therapy. Eur Haematol Touch Briefings: 2008; 2 58 60
48. Van Wyck D. B. Labile iron manifestations and clinical implications. J Am Soc Nephrol: 2004; 15 107 111